摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(3-amino-propoxy)-aniline | 31352-38-2

中文名称
——
中文别名
——
英文名称
4-(3-amino-propoxy)-aniline
英文别名
4-(3-Amino-propoxy)-anilin;4-(3-Amino-propyloxy)-anilin;4-(3-Aminopropoxy)aniline
4-(3-amino-propoxy)-aniline化学式
CAS
31352-38-2
化学式
C9H14N2O
mdl
——
分子量
166.223
InChiKey
JCNPEXXAAOOIJV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    331.5±22.0 °C(Predicted)
  • 密度:
    1.090±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.3
  • 重原子数:
    12
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    61.3
  • 氢给体数:
    2
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Discovery of TD-4306, a long-acting β2-agonist for the treatment of asthma and COPD
    摘要:
    A multivalent approach focused on amine-based secondary binding groups was applied to the discovery of long-acting inhaled beta(2)-agonists. Addition of amine moieties to the neutral secondary binding group of an existing beta(2)-agonist series was found to provide improved in vivo efficacy, but also led to the formation of biologically active aldehyde metabolites which were viewed as a risk for the development of these compounds. Structural simplification of the scaffold and blocking the site of metabolism to prevent aldehyde formation afforded a potent series of dibasic beta(2)-agonists with improved duration of action relative to their monobasic analogs. Additional optimization led to the discovery of 29 (TD-4306), a potent and selective beta(2)-agonist with potential for once-daily dosing. (C) 2014 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2014.04.095
  • 作为产物:
    参考文献:
    名称:
    Ishidate et al., Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1952, vol. 72, p. 88,89
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo
    申请人:Arrowhead Madison Inc.
    公开号:US20150045573A1
    公开(公告)日:2015-02-12
    The present invention is directed compositions for delivery of RNA interference (RNAi) triggers to integrin positive tumor cells in vivo. The compositions comprise RGD ligand-targeted amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or conjugate) are further covalently linked to an RNAi trigger.
    本发明涉及用于在体内向整合素阳性肿瘤细胞传递RNA干扰(RNAi)触发剂的组合物。这些组合物包括以RGD配体为靶向的两性膜活性聚胺,其可逆修饰为酶可切割的二肽-酰胺基苯甲酸酯掩蔽剂。修饰掩蔽了聚合物的膜活性,而可逆性提供了生理响应性。可逆修饰的聚胺(动态聚结合物或结合物)进一步共价连接到RNAi触发剂。
  • Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors
    作者:Mark E. McDonnell、Haiyan Bian、Jay Wrobel、Garry R. Smith、Shuguang Liang、Haiching Ma、Allen B. Reitz
    DOI:10.1016/j.bmcl.2014.01.001
    日期:2014.2
    We designed a series of anilino-indoylmaleimides based on structural elements from literature JAK3 inhibitors 3 and 4, and our lead 5. These new compounds were tested as inhibitors of JAKs 1, 2 and 3 and TYK2 for therapeutic intervention in rheumatoid arthritis (RA). Our requirements, based on current scientific rationale for optimum efficacy against RA with reduced side effects, was for potent, mixed JAK1 and 3 inhibition, and selectivity over JAK2. Our efforts yielded a potent JAK3 inhibitor 11d and its eutomer 11e. These compounds were highly selective for inhibition of JAK3 over JAK2 and TYK. The compounds displayed only modest JAK1 inhibition. (C) 2014 Elsevier Ltd. All rights reserved.
  • 287. Attempts to find new antimalarials. Part X. 8-Amino-6-γ-aminopropoxyquinoline and some related substances
    作者:K. Matejka、Robert Robinson
    DOI:10.1039/jr9340001322
    日期:——
  • POLYCONJUGATES FOR DELIVERY OF RNAI TRIGGERS TO TUMOR CELLS IN VIVO
    申请人:Arrowhead Pharmaceuticals, Inc.
    公开号:EP3030244B1
    公开(公告)日:2021-04-21
  • US9487556B2
    申请人:——
    公开号:US9487556B2
    公开(公告)日:2016-11-08
查看更多